Thursday, Guardant Health, Inc. (GH) announced a multi-year strategic collaboration with Nuvalent, Inc. (NUVL) to support the development and potential commercialization of the latter's oncology pipeline using the tissue and liquid offerings of the Guardant Infinity platform.
Under the partnership, the companies will utilize Guardant's portfolio of tissue and liquid biopsy tests to support certain Nuvalent global clinical studies.
They will also evaluate opportunities to develop Guardant tissue and/or liquid biopsy assays as companion diagnostics to support potential regulatory approvals of Nuvalent's current investigational candidates.
Further, the companies will collaborate on the global commercialization of Nuvalent's product candidates, if approved, and Guardant companion diagnostics across major global key markets.
Currently, GH is trading at $84.36, up 1.14 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.